Woodley Farra Manion Portfolio Management Inc. continued to hold its stake in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,427 shares of the company’s stock at the close of the 2nd quarter. Woodley Farra Manion Portfolio Management Inc.’s holdings in Eli Lilly and were worth $1,599,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Ronna Sue Cohen increased its holdings in shares of Eli Lilly and by 0.4% in the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after purchasing an additional 9 shares during the period. Accredited Investors Inc. increased its holdings in shares of Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after purchasing an additional 14 shares during the period. Northwest Quadrant Wealth Management LLC increased its holdings in shares of Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after purchasing an additional 19 shares during the period. Oakworth Capital Inc. increased its holdings in shares of Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after purchasing an additional 20 shares during the period. Finally, Sfmg LLC increased its holdings in shares of Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after purchasing an additional 20 shares during the period. Institutional investors own 75.48% of the company’s stock.

Shares of Eli Lilly and Company (LLY) opened at $82.86 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09. The stock has a market capitalization of $91,710.21, a price-to-earnings ratio of 20.36, a PEG ratio of 1.83 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the prior year, the business earned $0.88 earnings per share. The business’s revenue was up 9.0% on a year-over-year basis. sell-side analysts anticipate that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. Eli Lilly and’s dividend payout ratio is currently 98.58%.

LLY has been the topic of a number of recent research reports. Credit Suisse Group lowered Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their target price for the company from $84.23 to $88.00 in a report on Tuesday, October 10th. Piper Jaffray Companies reissued a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a report on Thursday, August 31st. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a report on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating and issued a $89.00 target price (down previously from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Finally, BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a “sell” rating in a report on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Hold” and an average target price of $89.76.

WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/14/woodley-farra-manion-portfolio-management-inc-maintains-holdings-in-eli-lilly-and-company-lly.html.

In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now directly owns 123,682,287 shares in the company, valued at $10,207,499,146.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders sold 772,003 shares of company stock worth $64,837,441 over the last 90 days. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.